Peripheral arterial disease: Diagnosis and management

被引:11
作者
Arain, Faisal A. [1 ]
Cooper, Leslie T., Jr. [1 ]
机构
[1] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Peripheral arterial disease is a common but underdiagnosed and undertreated disorder with substantial morbidity and mortality. The pathophysiology of peripheral arterial disease and the risk factors for developing it are similar to those for atherosclerotic disease occurring at other sites. Peripheral arterial disease can be diagnosed accurately with simple, noninvasive, office-based tests that measure the severity of the disease and provide valuable prognostic information. Optimal medical therapy includes a supervised exercise program, tobacco cessation, and modification of treatable risk factors. Cilostazol can improve pain-free and peak walking distances in patients with intermittent claudication. As a general rule, patients with lifestyle-limiting claudication who do not respond to medical management or those with critical limb ischemia should be referred to a vascular specialist for consideration of revascularization.
引用
收藏
页码:944 / 950
页数:7
相关论文
共 47 条
[1]
Risk factors for progression of peripheral arterial disease in large and small vessels [J].
Aboyans, Victor ;
Criqui, Michael H. ;
Denenberg, Julie O. ;
Knoke, James D. ;
Ridker, Paul M. ;
Fronek, Arnost .
CIRCULATION, 2006, 113 (22) :2623-2629
[2]
RETRACTED: Brief communication: Ramipril markedly improves walking ability in patients with peripheral arterial disease - A randomized trial (Retracted article) [J].
Ahimastos, AA ;
Lawler, A ;
Reid, CM ;
Blombery, PA ;
Kingwell, BA .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (09) :660-664
[3]
Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[4]
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[5]
The importance of increasing public and physician awareness of peripheral arterial disease [J].
Becker, GJ ;
McClenny, TE ;
Kovacs, ME ;
Raabe, RD ;
Katzen, BT .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2002, 13 (01) :7-11
[6]
Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death) [J].
Beckman, JA ;
Preis, O ;
Ridker, PM ;
Gerhard-Herman, M .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (10) :1374-1378
[7]
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase:: a potential new risk factor for coronary artery disease [J].
Caslake, MJ ;
Packard, CJ ;
Suckling, KE ;
Holmes, SD ;
Chamberlain, P ;
Macphee, CH .
ATHEROSCLEROSIS, 2000, 150 (02) :413-419
[8]
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[9]
Creasy T S, 1990, Eur J Vasc Surg, V4, P135, DOI 10.1016/S0950-821X(05)80427-X
[10]
MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL-DISEASE [J].
CRIQUI, MH ;
LANGER, RD ;
FRONEK, A ;
FEIGELSON, HS ;
KLAUBER, MR ;
MCCANN, TJ ;
BROWNER, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (06) :381-386